Cardiometabolic Disorders

Top Story

IRIS: Pioglitazone prevents secondary CV events in high-risk patients

September 18, 2017

Nondiabetic, insulin-resistant patients at elevated risk for stroke or MI derive a greater benefit from pioglitazone compared with those at lower risk, but fracture risk is also higher, according to a secondary analysis of data from the IRIS trial.

Walter N. Kernan, MD, professor of medicine at Yale School of Medicine, and colleagues enrolled 3,876 participants (mean age, 63 years) with qualifying ischemic stroke or transient ischemic attack within 180 days of entry with insulin resistance but without type 1 or type 2 diabetes from February 2005 to January 2013.

Meeting News

Twice-daily aspirin may confer CV benefit in type 2 diabetes

September 18, 2017
Patients with type 2 diabetes but without existing cardiovascular disease experienced a time-dependent increase in platelet aggregation in the 24 hours after once-daily…
Meeting News

CV death risk decreases with evolocumab in atherosclerotic disease

September 15, 2017
The risks for cardiovascular death, myocardial infarction and stroke are reduced in adults with atherosclerotic disease with or without diabetes treated with the PCSK9…
In the Journals

Risk for CHD, HF, cerebrovascular disease increases in metabolically healthy obese

September 11, 2017
Patients who were metabolically healthy obese had a higher risk for CHD, HF and cerebrovascular disease compared with those who were normal weight and metabolically…
More Headlines »

Improving Bone Strength and Reducing Fracture Risk in Osteoporosis

This activity is supported by an educational grant from Merck & Co., Inc.

Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue leading to reduced…
More »
Meeting News Coverage

VIDEO: PEGASUS-TIMI 54 analysis shows reduced risk for MACE in patients with diabetes

April 7, 2016
More »
Resource Centers

Practical Lipidology®: Volume 3, Number 1

This activity is supported by an educational grant from Amgen

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing…
More »